Updates in chronic graft-versus-host disease management

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Chronic graft-versus-host disease (cGvHD) is a major long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT).
• Traditional management relies heavily on corticosteroids, leading to significant side effects and impaired quality of life.

Purpose of the Study:

• To review recent advancements in understanding cGvHD pathogenesis.
• To discuss novel targeted therapies and their impact on patient outcomes.
• To provide perspectives on future cGvHD management strategies.

Main Methods:

• Review of recent scientific literature on cGvHD.
• Analysis of clinical trial data for newly approved and investigational drugs.
• Discussion of biological pathways implicated in cGvHD.

Main Results:

• Significant progress in understanding cGvHD biology has enabled targeted therapies.
• Ibrutinib, ruxolitinib, and belumosudil show improved outcomes in steroid-refractory cGvHD.
• These novel agents minimize corticosteroid use, preserving function and improving quality of life.

Conclusions:

• Targeted therapies represent a paradigm shift in managing steroid-refractory cGvHD.
• New drugs improve quality of life and overall survival for allo-HCT recipients.
• Ongoing research into novel agents promises further improvements in cGvHD treatment.